During the last decade, advances in molecular biology have revealed an increasing number of potential molecular targets, including peptide receptors and peptide-related biomolecules.
Their ability to bind an extensive range of molecular targets, including small molecules, proteins, and ions, with high affinity and specificity enables their use in diverse diagnostic, therapeutic, imaging, and gene-regulatory applications.
Pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) is a novel antifolate/antimetabolite with activity in breast cancer and has well-defined molecular targets, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.
Peroxynitrite (ONOO−) is an extremely reactive oxygen species in biological systems, and can react with a wide variety of molecular targets including proteins, lipids, and nucleic acids, eventually resulting in mitochondria dysfunction and cell death.
Our current study results show that the improvement in cardiac function in CLP-1+/− mice after ischemia reperfusion injury is achieved through the potentiation of redox signaling and their molecular targets including redox effector factor-1, nuclear factor erythroid 2-related factor, and NADPH oxidase 4 and the active usage of thioredoxin-1, thioredoxin-2, glutaredoxin-1 and glutaredoxin-2.
As can be seen in Fig. 3, the natural products in NPCARE are distributed among the diverse molecular targets including 58 classes of proteins that have served as the receptor models in the development of anticancer medicines.
Possible molecular targets include angiogenic growth factors and their receptors, proteinases, coagulation factors, junctional/adhesion molecules and extracellular matrix (ECM) components.
Potential molecular targets include the protein kinase A and C phosphorylation sites on troponin I, which, when phosphorylated, mediate a reduction in calcium sensitivity and a reduction in maximal actomyosin adenosinetriphosphatase activity, respectively.
68 Other molecular targets include tyrosine kinases, and the drug imatinib mesylate has been reported to be anti-fibrotic through inhibiting downstream molecules that are required for the TGF-β response while having an additional anti-fibrotic role by also inhibiting platelet-derived growth factor signaling.
But drugs often have more than one molecular target, including targets not relevant to the diseases they're designed to treat.
Molecular targeting agents, including sorafenib, sunitinib, and/or everolimus, were administered to 7 patients after 2008.
